This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hematology				
Anemia	IL-17 (IL-17A)	<p><i>In vitro</i> and mouse studies suggest that early treatment with anti-IL-17 antibodies could help treat aplastic anemia (AA). In bone marrow and peripheral blood cells from AA patients, levels of IL-17-expressing T helper type 17 (Th17) cells were higher than those in healthy controls, and greater IL-17 expression correlated with disease severity. In a mouse model of bone marrow failure, early treatment with an anti-IL-17 antibody reduced Th17 cell levels, delayed bone marrow failure and reduced severity compared with late treatment. Next steps could include testing anti-IL-17 antibodies in AA patients.</p> <p>Novartis AG has AIN457, an anti-IL-17 mAb, in clinical testing for various autoimmune and ophthalmic indications.</p> <p>NovImmune S.A. has the antibody NI-1401 in preclinical testing to treat autoimmune diseases.</p> <p>SciBX 3(35); doi:10.1038/scibx.2010.1067 Published online Sept. 9, 2010</p>	Patent and licensing status unavailable	<p>Peffault de Latour, R. <i>et al. Blood</i>; published online Aug. 23, 2010; doi:10.1182/blood-2010-01-266098</p> <p>Contact: Regis Peffault de Latour, National Institutes of Health, Bethesda, Md. e-mail: regis.peffaultdelatour@sls.aphp.fr</p>